Bernadette Chadefaux-Vekemans

Endogenous hydrogen sulfide overproduction in Down syndrome

The cystathionine beta synthase (CBS) gene is localized on chromosome 21 (21q22.3). This enzyme is one of three enzymes able to produce hydrogen sulfide. CBS is overexpressed in Down syndrome with levels 166% of normal values in fibroblasts [Chadefaux et al., 1985] and 1,200% in myeloblasts [Taub et al., 1999]. The CBS overexpression could induceanoverproduction ofhydrogen sulfide in Down syndrome patients, and this overproduction is potentially able to induce some of the clinical signs of Down syndrome such as hypotonia and mental retardation. As thiosulfate is the main catabolite of hydrogen sulfide [Kangas and Savolainen, 1987], we compared the levels of this molecule in the urine of Down syndrome patients and control subjects. Human erythrocytes containvarious formsofhemoglobin.These include sulfhemoglobin, which is formed by transformation of the ferric derivative of hemoglobin, methemoglobin. Sulfhemoglobin production requires hydrogen sulfide (or another sulfide) andmethemoglobin [Nichols et al., 1968]. The determination of sulfhemoglobin in erythrocytes was therefore also used to assess hydrogen sulfide production in Down syndrome. Informed consent was obtained from Down syndrome patients and their parents and from controls. The subjects were assigned to three groups. Group 1 (diet-matched pairs) consisted of 21 pairs of subjects (17 of them were included in a previously published study [Belardinelli et al., 2001]. In each volunteer family, one Down syndrome subject and one relative (mother or father in most families, brother or sister in rare cases) were given identical diets. This group consisted of 13 male and 8 female Down syndrome subjects and matched controls (10 male and 11 female). Sulfur compounds were excluded from the daily treatments of Downsyndromepatientsandcontrols.Group2consisted of 30 patients with Down syndrome (19 male and 11 female) and 20 controls (volunteers from the laboratory; 10 male and 10 female). In this group, age distribution was similar for Down syndrome patients and controls (Table I). The first urine produced in the morning was collected from the subjects of groups 1 and 2 in vials containing boric acid used as a preservative. Thiosulfate was determined in urine by colorimetry after chromatographic separation [Voroteliak et al., 1993]. Creatinine was determined by the manual Jaffe method. Group 3 consisted of 60 Down syndrome patients (33 male and 27 female) and 60 age-matched controls (35 male and 25 female). Venous blood was withdrawn in fasting subjects of group 3; erythrocytes were separated by centrifugation and hemolysates were frozen until use. Sulfhemoglobin was determined by spectrophotometry and the results are expressed as ratio of absorbance (A) at various wawelengths: (A622 nm A636 nm)/(A535 nmþA560 nm) 0.5 10. This ratio was used because it is not affected by differences between the respective concentrations of oxygenated and unoxygenated hemoglobin. A significant difference was observed in the urinary excretion of thiosulfate between Down syndrome patients and relatives of group 1 (diet-matched pairs) (Table I). In group 2, statistical analysis indicates that the differences in thiosulfate excretion persisted. To confirm that hydrogen sulfide was overproduced in Down syndrome patients, we studied erythrocyte sulfhemoglobin content in subjects of group 3. The wawelength ratios were 2.51 0.04 and 2.00 0.08 (SEM) for patientswithDownsyndrome and controls, respectively (P<0.001). We obtained two different types of evidence for the overproduction of hydrogen sulfide in Down syndrome patients. The main function of CBS is to catalyze the first step of transsulphuration pathway, producing cysteine from homocysteine. In vivo, the high level of CBS activity in Down syndrome results in low concentrations of the substrate of CBS (homocysteine) in plasma [Chadefaux et al., 1988]. CBS also has another enzymatic activity: the production of hydrogen sulfide from cysteine [Stipanuck and Beck, 1982]. The endogenous productionofhydrogensulfidecanbeestimatedbymonitoring thiosulfate excretion in urine (31 mmoles/day in control adults) [Sorbo and Ohman, 1978]. After hydrogen sulfide poisoning, the excretion of thiosulfate in urine increased significantly [Kangas and Savolainen, *Correspondence to: Pierre Kamoun, Biochimie B–Tour Lavoisier, Hôpital Necker Enfants Malades, 149, rue de Sèvres, 75743 Paris Cedex 15, France. E-mail: pierre.kamoun@nck.ap-hop-paris.fr

A NEW MOUSE MODEL FOR THE TRISOMY OF THE ABCG1-U2AF1 REGION REVEALS THE COMPLEXITY OF THE COMBINATORIAL GENETIC CODE OF DOWN SYNDROME

Mental retardation in Down syndrome (DS), the most frequent trisomy in humans, varies from moderate to severe. Several studies both in human and based on mouse models identified some regions of human chromosome 21 (Hsa21) as linked to cognitive deficits. However, other intervals such as the telomeric region of Hsa21 may contribute to the DS phenotype but their role has not yet been investigated in detail. Here we show that the trisomy of the 12 genes, found in the 0.59 Mb (Abcg1–U2af1) Hsa21 sub-telomeric region, in mice (Ts1Yah) produced defects in novel object recognition, open-field and Y-maze tests, similar to other DS models, but induces an improvement of the hippocampal-dependent spatial memory in the Morris water maze along with enhanced and longer lasting long-term potentiation in vivo in the hippocampus. Overall, we demonstrate the contribution of the Abcg1–U2af1 genetic region to cognitive defect in working and short-term recognition memory in DS models. Increase in copy number of the Abcg1–U2af1 interval leads to an unexpected gain of cognitive function in spatial learning. Expression analysis pinpoints several genes, such as Ndufv3, Wdr4, Pknox1 and Cbs, as candidates whose overexpression in the hippocampus might facilitate learning and memory in Ts1Yah mice. Our work unravels the complexity of combinatorial genetic code modulating different aspect of mental retardation in DS patients. It establishes definitely the contribution of the Abcg1–U2af1 orthologous region to the DS etiology and suggests new modulatory pathways for learning and memory.

Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease

Homocysteine is a graded risk factor for the incidence of stroke and for the degree of carotid atherosclerosis. Homocysteine is also a graded risk factor for the incidence of myocardial infarction but we do not know its precise relations to the severity of atherosclerosis in coronary patients. Seventy five symptomatic coronary patients were recruited for the study. Fifty of these patients had coronary artery disease only and were compared in a case-control manner to 50 healthy controls matched for age and sex. The 25 other coronary patients had also symptoms in another atherosclerotic territory (cerebral, peripheral or both) and were also compared to 25 matched controls. Mean plasma homocysteine level was significantly higher in coronary patients than in controls (11.7 +/- 0.7 mumol l-1, n = 50 versus 9.9 +/- 0.5 mumol l-1, n = 50, p < 0.05). Homocysteine in patients with symptomatic atherosclerosis in two or three arterial sites was 15.7 +/- 1.5 mumol l-1 which differed significantly from matched controls and from patients with coronary artery disease only (p = 0.01). The extent of coronary atherosclerosis evaluated by an angiographic coronary score correlated weakly to plasma homocysteine levels (r = 0.25, p < 0.05). The patients with both hypertension and high levels of homocysteine (> 11.3 mumol l-1, median value) had more severe coronary atherosclerosis (coronary score of 16.3 +/- 2.3 versus 11.9 +/- 0.9, p < 0.05) and more diffuse atherosclerosis (number of atherosclerotic territories of 1.5 +/- 0.2 versus 1.2 +/- 0.7, p = 0.08) than the coronary patients without this association. There were no other high risk association when considering the other classical risk factors. Thus, the highest levels of homocysteine were present in patients with coronary disease and another symptomatic localisation of atherosclerosis. A small gradient in the extent of coronary atherosclerosis was found with increasing levels of homocysteine. The presence of both hypertension and hyperhomocysteinemia was associated with more severe coronary atherosclerosis.

Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy

Cystinosin, the lysosomal cystine exporter defective in cystinosis, is the founding member of a family of heptahelical membrane proteins related to bacteriorhodopsin and characterized by a duplicated motif termed the PQ loop. PQ-loop proteins are more frequent in eukaryotes than in prokaryotes; except for cystinosin, their molecular function remains elusive. In this study, we report that three yeast PQ-loop proteins of unknown function, Ypq1, Ypq2, and Ypq3, localize to the vacuolar membrane and are involved in homeostasis of cationic amino acids (CAAs). We also show that PQLC2, a mammalian PQ-loop protein closely related to yeast Ypq proteins, localizes to lysosomes and catalyzes a robust, electrogenic transport that is selective for CAAs and strongly activated at low extracytosolic pH. Heterologous expression of PQLC2 at the yeast vacuole rescues the resistance phenotype of an ypq2 mutant to canavanine, a toxic analog of arginine efficiently transported by PQLC2. Finally, PQLC2 transports a lysine-like mixed disulfide that serves as a chemical intermediate in cysteamine therapy of cystinosis, and PQLC2 gene silencing trapped this intermediate in cystinotic cells. We conclude that PQLC2 and Ypq1–3 proteins are lysosomal/vacuolar exporters of CAAs and suggest that small-molecule transport is a conserved feature of the PQ-loop protein family, in agreement with its distant similarity to SWEET sugar transporters and to the mitochondrial pyruvate carrier. The elucidation of PQLC2 function may help improve cysteamine therapy. It may also clarify the origin of CAA abnormalities in Batten disease.

Pyruvate carboxylase deficiency: Metabolic characteristics and new neurological aspects

Pyruvate carboxylase (PC) deficiency is a rare metabolic disease. Recently, therapeutic possibilities have been introduced. We aimed to report the largest series of the B type of PC deficiency, focusing on some neurological aspects that have not yet been documented.

Methylenetetrahydrofolate Reductase Polymorphism in the Etiology of Down Syndrome

A methylenetetrahydrofolate reductase polymorphism (677 C/T mutation) was recently implicated in the etiology of Down syndrome. We studied a cohort of 85 women carrying fetuses with Down syndrome and found no difference in the frequencies of the three groups of subjects (C/C, C/T, T/T) between Down syndrome mothers and controls.

Structural insights on pathogenic effects of novel mutations causing pyruvate carboxylase deficiency.

Pyruvate carboxylase (PC), a key enzyme for gluconeogenesis and anaplerotic pathways, consists of four domains, namely, biotin carboxylase (BC), carboxyltransferase (CT), pyruvate carboxylase tetramerization (PT), and biotin carboxyl carrier protein (BCCP). PC deficiency is a rare metabolic disorder inherited in an autosomal recessive way. The most severe form (form B) is characterized by neonatal lethal lactic acidosis, whereas patients with form A suffer chronic lactic acidosis with psychomotor retardation. Diagnosis of PC deficiency relies on enzymatic assay and identification of the PC gene mutations. To date, six mutations of the PC gene have been identified. We report nine novel mutations of the PC gene, in five unrelated patients: three being affected with form B, and the others with form A. Three of them were frameshift mutations predicted to introduce a premature termination codon, the remaining ones being five nucleotide substitutions and one in frame deletion. Impact of these mutations on mRNA was assessed by RT‐PCR. Evidence for a deleterious effect of the missense mutations was achieved using protein alignments and three‐dimensional structural prediction, thanks to our modeling of the human PC structure. Altogether, our data and those previously reported indicate that form B is consistently associated with at least one truncating mutation, mostly lying in CT (C‐terminal part) or BCCP domains, whereas form A always results from association of two missense mutations located in BC or CT (N‐terminal part) domains. Finally, although most PC mutations are suggested to interfere with biotin metabolism, none of the PC‐deficient patients was biotin‐responsive. Hum Mutat 0:1–7, 2009.

Reliability of biochemical parameters used in prenatal diagnosis of combined methylmalonic aciduria and homocystinuria

Prenatal diagnosis for combined methylmalonic aciduria and homocystinuria was performed in five at‐risk pregnancies by determination of methylmalonic acid (MMA) and total homocysteine (Hcy) in amniotic fluid supernatant. The incorporation rate of [14C] propionate (±OHCbl) and the synthesis of cobalamin derivatives in cultured amniocytes were investigated as well as the [14C] MTHF incorporation rate in intact chorion biopsy. Our experience showed that total Hcy and MMA were clearly elevated in amniotic fluid of affected fetuses. Both the study of [14C] propionate incorporation and that of cobalamin synthesis in cultured amniocytes are useful to confirm the results of metabolite determination. The incorporation of [14C] MTHF in intact chorion biopsy seems not to be a reliable diagnostic method.

GESTATIONAL AGE‐RELATED REFERENCE VALUES FOR AMNIOTIC FLUID AMINO ACIDS: A USEFUL TOOL FOR PRENATAL DIAGNOSIS OF AMINOACIDOPATHIES

In this study we have measured the concentration of 24 amino acids and total homocysteine in amniotic fluids obtained between the tenth and 32nd week of gestation from pregnancies not at risk for metabolic diseases. These results are used as reference values to which are compared values obtained from pregnancies at risk for citrullinaemia, argininosuccinic aciduria, HHH (hyperornithinaemia, hyperammonaemia and homocitrullinaemia) syndrome, cobalamin metabolism disorders (CblC or CblD), and sulphite oxidase deficiency. We discuss the helpfulness of amino acid analysis in amniotic fluid for prenatal diagnosis of aminoacidopathies.

Gestational age-related reference values for amniotic fluid organic acids.

Normative data for amniotic fluid (AF) levels of organic acids at different gestational ages are lacking. They can provide a useful framework to investigate the accuracy of prenatal diagnosis for organic acidemias.